Skip to main content
OpenTrials
Completed

NCT Number: NCT00787748

COPD and Cardiovascular Risk in the Population

The prevalence of chronic obstructive pulmonary disease (COPD) in patients with cardiovascular disease (CVD) is unknown, and whether or not COPD is adequately diagnosed and treated in these patients has not been investigated before.

We hypothesized that the prevalence of COPD would be significantly higher (30%) in patients with CVD than in the general population. Besides, we anticipated that COPD, a potentially treatable CV risk factor, would be undiagnosed in more than 80% of CVD patients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Obstructive Pulmonary Disease Cardiovascular Disease Cardiovascular Diseases Chronic Disease Disease Attributes Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Pulmonary Disease, Chronic Obstructive Respiratory Tract Diseases

Age range

40 year–81 year

Sex eligibility

All sexes

Study type

Observational

Primary location

CIMERA

Bunola, Balearic Islands, 07110, Spain

About this study

We aim to compare clinical and spirometric data in three groups of individuals. Two of them are participants in an ongoing population-based study (CORSAIB) aimed at investigating the distribution of CVD risk factors in the general population of the Balearic Islands, Spain. The design and full methodological details of the CORSAIB study have been published elsewhere (Rigo F, et al. Rev Clin Espa 2005). A third group will include patients with stable CVD regularly visited at the referral hospital of our community.

Inclusion criteria

for the study are male and female individuals, aged 40 to 81 years, residents of the Balearic Islands, and who are willing to participate in this research.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • residents of the Balearic Islands
  • willing to participate in this research
  • able to sign the written consent form

Exclusion criteria

  • none

Treatment and study plan

Primary outcomes

  1. Prevalence of COPD defined according to the current GOLD guidelines as a post-bronchodilator forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) <0.7.

    Time frame: Current

Secondary outcomes

  1. Underdiagnosis of COPD

    Time frame: Current

  2. Undertreatment of COPD

    Time frame: Current

Sponsors and collaborators

Lead sponsor

Cimera

Network

Collaborators

  • Fondo de Investigacion Sanitaria

Registry information

Acronym: CORSAIB

Important dates

Study start
2006
Primary completion
2008
Study completion
2008
First posted
Nov 7, 2008
Registry last updated
Jun 15, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.